ASBMR: Romosozumab reduces fracture rate in osteoporosis

September 12, 2017

(HealthDay)—Romosozumab treatment followed by alendronate is linked to reduced risk of fractures versus alendronate alone for postmenopausal women with osteoporosis, according to a study published online Sept. 11 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society for Bone and Mineral Research, held from Sept. 8 to 11 in Denver.

Kenneth G. Saag, M.D., from the University of Alabama in Birmingham, and colleagues randomized 4,093 postmenopausal women with osteoporosis and a fragility fracture to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months, followed by open-label alendronate in both groups.

The researchers found that the of new vertebral fracture was 48 percent lower in the romosozumab-to-alendronate versus the alendronate-to-alendronate group (6.2 versus 11.9 percent; P < 0.001), over a period of 24 months. Clinical occurred in 9.7 and 13.0 percent of patients in the romosozumab-to-alendronate and the alendronate-to-alendronate groups, respectively (27 percent lower risk with romosozumab; P < 0.001). The risk of nonvertebral fractures was 19 percent lower in the romosozumab-to-alendronate versus the alendronate-to-alendronate group (8.7 versus 10.6 percent; P = 0.04) and the risk of was 38 percent lower (2.0 versus 3.2 percent; P = 0.02).

"In with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone," the authors write.

The study was partially funded by Amgen, the manufacturer of romosozumab.

Explore further: Alendronate effective, safe in 'oldest old' with prior fracture

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Alendronate effective, safe in 'oldest old' with prior fracture

September 7, 2017
(HealthDay)—Alendronate treatment reduces the risk of hip fracture in elderly patients with a prior fracture, with sustained safety, according to a study published online Aug. 30 in the Journal of Internal Medicine.

Romosozumab increases bone mineral density post-menopause

January 6, 2014
(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

June 15, 2017
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 show that in postmenopausal women with osteoporosis, 12 months of treatment with romosozumab is associated with large, rapid ...

Study looks at predicting fracture risk after women stop bisphosphonate therapy

May 5, 2014
Age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years.

Effective protection against hip fracture during cortisone treatment (Update)

July 11, 2017
There is effective protection against hip fracture for the many elderly people whose skeleton is declining in strength, as a side effect of cortisone treatment. If patients receive the osteoporosis medication alendronate, ...

Alendronate reduces adjacent-level vertebral fractures

December 30, 2013
(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue of Spine.

Recommended for you

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.

Cell-free DNA profiling informative way to monitor urinary tract infections

June 20, 2018
Using shotgun DNA sequencing, Cornell University researchers have demonstrated a new method for monitoring urinary tract infections (UTIs) that surpasses traditional methods in providing valuable information about the dynamics ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.